fda glp-1 warning news november 2025 Societies take stand against off-brand GLP-1s over safety concerns Last month, the FDA issued

2018;1864(9 Pt B):281421

Available from: Linda Gigliotti 1 , Hope Warshaw 2 , Alison Evert 3 , Colleen Dawkins 4 , Julie Schwartz 5 , Caroline Susie 6 , Robert Kushner 7 , Savitha Subramanian 8 , Deepa Handu 9 , Mary Rozga 10 Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care

After a week at 2 scoops, increase to 3 scoops

Patients with pre-existing diabetic retinopathy should be monitored closely, as rapid improvement in blood glucose control may temporarily worsen retinopathy

The recovery resources have shrunk

The SURMOUNT-1 trial tested the ability of tirzepatide to produce weight loss in people with obesity who do not have diabetes